Abstract: The invention provides transdermal patches comprising an adhesive and a composition comprising naltrexone and methyl oleate or isopropyl myristate, a kit comprising a plurality of such transdermal patches, a composition comprising naltrexone and methyl oleate, such a composition for use as a medicament, and compositions comprising naltrexone and methyl oleate or isopropyl myristate for use in the treatment of alcoholism or opiate addiction.

Abstract: A pramipexole transdermal patch for treatment of neurological disorders including Parkinson's disease that may be administered on a daily basis. The pramipexole transdermal patch of the present invention preferably comprises a drug-containing layer that comprises pramipexole or a pharmaceutically acceptable salt thereof at 2% to about 15% by weight of the drug-containing layer and at least two acrylic polymers wherein each polymer may further comprise carboxyl and/or hydroxyl functional groups. The pramipexole transdermal patch of the present invention may further comprise two or more permeation enhancers with combined pramipexole solubility of great than 50 mg/mL.

Abstract: Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

Abstract: The present invention provides a patch comprising a backing and an adhesive agent layer laminated on the backing, wherein the adhesive agent layer comprises ropinirole or a pharmaceutically acceptable salt thereof, an organic amine or an acid addition salt thereof, and an adhesive agent.

Abstract: The present invention relates to a topical spray composition comprising a biologically active vitamin D derivative or analogue and a corticosteroid, and its use in the treatment of dermal diseases and conditions.

Abstract: Certain exemplary embodiments can provide a system, machine, device, manufacture, circuit, composition of matter, and/or user interface adapted for and/or resulting from, and/or a method and/or machine-readable medium comprising machine-implementable instructions for, activities that can comprise and/or relate to, controlling delivery of a transdermally-delivered medication, certain embodiments including a flux controller.

Abstract: A medical active substance patch comprising a matrix of monolayer or multilayer configuration with at least one active substance-containing layer and comprising a backing layer connected with the matrix. The active substance patch is transparent or at least translucent, and in the state of having been applied to the skin of a first person, the patch has a lightness colour value L1 at a place of the skin covered by the patch which is not less than 50% and not more than 200% of a lightness colour value L2, L2 being the lightness value of the region of the skin of the same person which surrounds the applied patch. The same is true of the skin of a second or any other person, provided that for all the persons mentioned L2 is in the range from 5° to 100°, namely from 20° to 90°.

Abstract: Implantable medical device (IMD) such as leadless cardiac pacemakers may include a rechargeable power source. In some cases, the IMD may include a plurality of receiving coils that may capture a non-radiative near-field energy and then convert the near-field energy into electrical energy that may be used to recharge the rechargeable power source. Accordingly, since the rechargeable power source does not have to maintain sufficient energy stores in a single charge for the entire expected life of the IMD, the power source itself and thus the IMD, may be made smaller while still meeting device longevity expectations.

Abstract: An article having anti-microbial effect is provided. The article includes an occlusive layer; a substrate overlaying the occlusive layer, wherein the substrate having two opposing major surfaces; a metal oxide layer overlaying the substrate, wherein the metal oxide layer comprises a metal oxide and wherein the metal oxide layer comprises less than 40 wt. % non-oxidized metal; and a metal layer overlaying the metal oxide layer.

Abstract: A composition suitable for use in nicotine replacement therapy products includes a nicotine product that includes a synthetic nicotine that is substantially free of one or more contaminants and/or impurities normally associated with tobacco-derived nicotine. For example, the synthetic nicotine is substantially free of one or more of nicotine-1?-N-oxide, nicotyrine, nornicotyrine, 2?,3-bipyridyl, cotinine, anabasine, and/or anatabine. The composition further comprises one or more pharmaceutically acceptable excipients, additives and/or carriers. The nicotine replacement therapy products may include any number of such products, including transdermal nicotine delivery patches, nicotine gums, synthetic chewing tobacco, synthetic snuff, and synthetic strips (e.g., dissolvable synthetic tobacco). Additionally, a method of treating nicotine addiction includes administering a nicotine replacement composition, e.g., via a nicotine replacement therapy product, to a user.

Abstract: A process is described herein for applying antimicrobials to substrates to prevent the growth of biological agents. An antimicrobial-binder mixture is provided. The binder comprises guar gum, ammonium sulfate, urea, and methyl acryloid. The antimicrobial is an organo silane quarternary amine antimicrobial. The antimicrobial-binder mixture is ionized to comprise negatively charged particles. The antimicrobial-binder mixture is aerosolized to form fog. The fog is administered to the surface and dried.

Abstract: The present invention relates to a backing having a three-layer structure prepared by sticking together an inner fiber layer for holding a pasty preparation, a film layer having through-holes, and an air-permeable outer fiber layer which prevents leaking out of the pasty preparation or a liquid component exuded from the pasty preparation, and also relates to an aqueous patch using the backing which can be applied for a long time.

Abstract: The present disclosure relates to a film for oral hemostasis and wound protection and, more particularly, to a film for oral hemostasis and wound protection which, being attached to a wound area in an oral cavity, delays or prevents microbleeds and controls medicinal component release. The film provided by the present disclosure is capable of including a polyol, an alcohol and a biodegradable polymer in the state of partial swelling, thereby locally absorbing blood or pus or arresting hemorrhage. Moreover, due to its high elongation ratio, the film provided by the present disclosure is capable of maintaining its adhesive force even when having blood, saliva and pus absorbed inside an oral cavity and conveniently deforming according to the shape of a seriously corrugated local area, which causes only slight foreign body sensation even after a long period of time of attachment on to the local area.

Abstract: Provided herein is a water- and sweat-resistant transdermal drug delivery system for application to the skin of a mammal that comprises a patch having a diameter between 1 and 8 cm in length and a surface area between 4 and 8 cm2. Also provided are methods of producing the transdermal drug delivery system and methods of treatment comprising the use of the transdermal drug delivery system.

Abstract: The invention relates to a transdermal therapeutic system (TTS), comprising a backing layer, which is permeable to the active ingredient, at least one matrix layer, comprising fentanyl or an active agent analogous to fentanyl, based on polyacrylate and a protective layer to be removed before usage, characterized in that the polyacrylate polymer is self-adhesive, free of carboxyl groups, has a saturation solubility for fentanyl of 3 to 20 wt. %, preferably of 4 to 12 and particularly of 5 to 10 wt. % and the layers contain at least 80% of the included active ingredient in a molecularly-dispersed, dissolved form.

Abstract: A system and method of using a high-aspect ratio microdevice for treating, preventing or ameliorating a medical condition is provided.

Abstract: A microneedle unit including a microneedle having a first surface and a second surface opposite to the first surface, the microneedle being flexible and having one or more projections on the first surface, and a support member connected to the second surface of the microneedle such that the support member supports the microneedle. The support member includes an adhesive portion and a rigid portion connected to the adhesive portion, the adhesive portion is adhesive to skin and extends outside of the second surface in plan view of the second surface, and the rigid portion includes a rigid plate which is more rigid than the adhesive portion and the microneedle.

Abstract: A kit for mucosally administering a metastable supersaturated solution of a pharmaceutical active agent to a human patient includes a first compartment comprising a first composition comprising a pharmaceutical active agent in solution at or below equilibrium solubility, and a second composition comprising an acidic buffer. The first and second compartments maintain separation of the first and second compositions during storage, and allow for mixing of the first and second compositions to form a supersaturated solution above equilibrium solubility of the pharmaceutical active agent for immediate mucosal administration to a human patient. In one embodiment, the second composition comprises an acidic buffer and the supersaturated solution has an acidic pH. Alternatively, the second composition comprises a basic buffer and the supersaturated solution has a basic pH.

Abstract: This disclosure provides for an antimicrobial pressure sensitive adhesive composition that includes a sequestered peroxide source and devices that incorporate such a composition.

Abstract: The present invention discloses a method of treating a head and neck cancer or preventing the development of pre-malignant lesions to this cancer, by administering locally to the oral cavity, a sustained release drug delivery system comprising a drug for the treatment of this cancer or for the prevention of said lesions, and at least one polymer, such that said system is attached to a surface in the oral cavity and remains attached thereto for at least 1 hour, accompanied by release of the drug and maintaining an effective therapeutic concentration thereof in the cavity, for at least 1 hour. Further are disclosed a sustained release drug delivery system and a liquid precursor varnish composition to this system.

Abstract: Silicone acrylate copolymer composition, namely, silicone resin-acrylate copolymers and methods of preparing the same. The silicone acrylate composition may include a silicone resin coupled with an acrylate polymer via a linking group. The silicone acrylate composition may be formed by preparing an acrylate or a (meth)acrylate functional resin and carrying out acrylate polymerization in the presence of a functionalized resin. A silane-functional acrylate polymer may be prepared, followed by a reaction to couple a resin to the silane-functional acrylate polymer. The resulting copolymer may then be used as desired, e.g., added to a silicone and acrylate mixture to create a non-separating blend.

Abstract: Adhesive compositions exhibiting antimicrobial properties, good stability, long shelf lives and enhanced release of antimicrobial agents are described. In certain versions, the compositions also exhibit relatively high fluid handling capacities. The adhesive compositions inhibit microbial growth by more than 2 log after 24 hours contact and particularly more than 3.5 log after 6 hours contact. Also described are various medical articles using such adhesives and related methods.

Abstract: The present disclosure relates to polythioaminals with applications as carriers or delivery vehicles for therapeutic agents or other small molecule cargo. Polythioaminal block copolymer coupled to a therapeutic agent is a polymer-therapeutic conjugate that exhibits higher stability and longer life time in aqueous environments. The polythioaminal block copolymer coupled to a therapeutic agent can be synthesized by reacting hexahydrotriazines with a hydrophobic block precursor, a hydrophilic block precursor, a particle stabilizing segment precursor, and a cargo, such as a therapeutic agent, in a one pot synthesis. The ease of synthesizing the resulting polythioaminal block copolymer coupled to the therapeutic agent while offering the extended stability and polymer life time in aqueous environments make the polythioaminal block copolymer particularly attractive for therapeutic carriers.

Abstract: A method for producing an antibiotic-loaded transdermal patch including preparing a polymeric adhesive solution by dissolving a polymeric mixture in a solvent, preparing a plurality of antibiotic-loaded solid lipid nanoparticles (SLNs), forming a patch formulation by mixing the plurality of antibiotic-loaded SLNs and the polymeric adhesive solution, and forming a layer of the patch formulation on a substrate.

Abstract: A film is uniformly coated with a coating solution. The following formula is satisfied: 0<a×c/b<113 where (i) a is a diameter (mm) of a gravure roll, (ii) b is a ratio of a circumferential velocity of the gravure roll to a conveyance speed at which the film is conveyed, and (iii) c is a volume (mL/m2) of recesses of the gravure roll, which volume is measured per unit area of a circumferential surface of the gravure roll.

Abstract: A patch includes an adhesive layer and a release liner laminated on at least one surface of a backing. The adhesive layer comprises, as an adhesive base agent, at least one selected from the group consisting of acrylate-based adhesives and rubber-based adhesives, and the adhesive layer comprises 0.3 to 5% by mass of a nonfunctional silicone oil having a kinematic viscosity of 10 to 350 cSt at 25° C.

Abstract: Disclosed herein are orthopedic revision systems including a base member having a collar portion and at least one stabilization portion extending outwardly from the collar portion. The systems may further include a stem member having an attachment portion and a shaft portion, the stem member configured to be received at least partially through an opening in the collar portion such that the attachment portion lies adjacent the collar portion and the shaft portion lies adjacent the at least one stabilizing portion. In a method of performing revision surgery with such orthopedic systems includes forming an opening in the collar of the base member for receipt of the stem member by removing an inner portion of the collar portion and inserting the stem member at least partially through the opening in the collar portion such that the attachment portion lies adjacent the collar portion and the shaft member lies adjacent the at least one stabilizing portion.

Abstract: Polymeric matrices for the controlled release of medicaments for the topical transdermal use comprising copolymers of acrylic and/or methacrylic acid or esters thereof having a Tg lower than 0° C., whose free carboxy groups are salified with compatible organic or inorganic bases. The matrices of the invention allow to prepare therapeutical systems for the controlled-release of active principles through the transdermal route, thus solving stability, solubility and/or bioavailability problems of the active ingredient within the matrix.

Abstract: The invention relates to a transdermal therapeutic system, preferably a transdermal patch, having an active ingredient-containing matrix formed substantially of a water-insoluble base material, such as rubber and synthetic polymers, into which is incorporated water-soluble and/or water-swellable inclusion bodies, e.g. inclusion bodies formed from polyvinyl alcohol or polyethylene glycol, that further include micronized or nanoscale active ingredient particles.

Abstract: Provided herein are anhydrous compositions that include at least one viscosity increasing agent, at least one organic solvent and at least one humectant. Such compositions may also include at least one active pharmaceutical ingredient (API) and/or at least one water repellant. Related compositions, methods and kits are also provided.

Abstract: An apparatus for hand protection includes a flexible sheet that extends from a first end to a second end of the flexible sheet along a length thereof. Adhesive material is located on one side of the flexible sheet. A backing layer is on the adhesive material. The flexible sheet includes at least one finger opening closer to the first end than to the second end. The flexible sheet also includes a separation extending from the second and towards the first end. The separation separates the second and into a plurality of anchors. A method enables a flexible sheet with adhesive material thereon to be applied to a person's hands. Fingers are inserted through one or more finger openings. The backing layer is removed. The flexible sheet, including anchors formed by a separation extending from an end of the flexible sheet are adhered around the person's hand.

Abstract: An abuse deterrent transdermal patch comprising a multilaminate. The multilaminate can comprise a first layer comprising an opioid analgesic compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable pressure sensitive adhesive. The multilaminate can further comprise a second layer comprising an opioid antagonist, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adhesive. In addition, the multilaminate can further comprise a barrier layer disposed between the first and second layers.

Abstract: The present invention relates to the field of electrotherapy and measuring by means of electric cur-rents for diagnostic purposes, and more particularly to an electrode arrangement for facilitating wound healing, a method for measuring wound healing and a wound dressing having an electrode arrangement. A wound dressing according is described which includes at least two impedance reference electrodes, a frame like counter-electrode and stimulation electrodes in a form of an array; and a bioadhesive affinity layer surrounding the stimulation electrodes; said wound dressing being suited for applying on top of the wound so that the stimulation electrode array is on the wound area, and that the at least two impedance reference electrodes and the frame like counter-electrode are suited for placing in contact with the healthy skin surrounding the wound area; which electrodes, are suited for applying LIDC type electrical stimulation current to the wound area and for bioimpedance measurement.

Abstract: The present invention relates to a transdermal patch comprising a pharmaceutical formulation, the formulation comprising ropivacaine or an opioid, a pharmaceutically-acceptable adhesive and optionally one or more excipients selected from the group consisting of carrier oils, penetration enhancers and hydrophilic materials. The present invention also relates to methods of preparation of such a pharmaceutical formulation, as well as the use of such a transdermal patch in the treatment of pain (e.g. nociceptive and/or neuropathic pain).

Abstract: A wound dressing according to the present invention comprises at least two impedance reference electrodes, a frame like counter-electrode and stimulation electrodes in a form of an array; and a bioadhesive affinity layer surrounding the stimulation electrodes; said wound dressing being suited for applying on top of the wound so that the stimulation electrode array is on the wound area, and that the at least two impedance reference electrodes and the frame like counter-electrode are suited for placing in contact with the healthy skin surrounding the wound area; which electrodes, are suited for applying LIDC type electrical stimulation current to the wound area and for bioimpedance measurement. The wound dressing according to the present invention provide a continuous, non-invasive and objective solution for monitoring chronic wound healing without disturbing the delicate healing process.

Abstract: Disclosed is a fentanyl-containing adhesive preparation for external use, wherein an adhesive layer is laminated on a supporting body. The adhesive layer contains SIS, a tackifier resin that is composed of a rosin resin and terpene resin, and a softener that is composed of a plybutene and a liquid paraffin. The adhesive layer also contains fentanyl as an active ingredient. The fentanyl-containing adhesive preparation for external use has excellent skin permeation of fentanyl and high preparation stability, without suffering from crystallization of fentanyl during storage.

Abstract: A transparent solid glue, in mass percentage comprises: 10.0%-50.0% of glycerol, 5.0%-20.0% of propylene glycol, 5.0%-30.0% of sticky substance, 1.0%-10.0% of stearic acid, 0-5.0% of vegetable oil, 0.5%-5.0% of protopine, 0.1%-5.0 of excipient, 0.1%-0.5% of preservative, and 5.0%-70.0% of deionized water, wherein the excipient is C12-16 saturated or unsaturated fatty acid salt. The prepared transparent solid glue has high initial viscosity; and the drying time is controllable so that the gluing position of the objects to be glued can be adjusted according to actual requirements, which is convenient to use, and the glue exhibits strong adhesion after completely drying. Meanwhile, the addition of protopine causes the pH of the solid glue to be between 10.49-10.99, and accordingly the solid glue is an environmentally friendly solid glue. Within a temperature range from ?5° C. to 40° C., this solid glue is widely applicable to gluing paper, wood pieces, photographic paper, paperboards and etc.

Abstract: A patch for a nail for treating dermatophytosis which includes a pressure-sensitive adhesive layer containing an acrylic-based pressure-sensitive adhesive and 2-(3, 5-dimethyl-1H-pyrazol-1-yl)-5-methylphenol or a salt thereof, wherein the acrylic-based pressure sensitive adhesive contains a copolymer of 2-ethylhexyl acrylate and N-vinylpyrrolidone, and wherein a mass ratio of the 2-ethylhexyl acrylate and the N-vinylpyrrolidone is 70:30 to 90:10.

Abstract: The present invention pertains to antimicrobial compositions comprising inter alia at least one alkenyl- and/or alkynyl-substituted polysiloxane, at least one polysiloxane comprising silicon-bonded hydrogen atoms, and at least one hydrosilylation catalyst, as well as antimicrobial silicone gels, wound dressings, and methods of preparing the above.

Abstract: The present invention relates to an acrylic pressure-sensitive adhesive composition, and more particularly, to an acrylic pressure-sensitive adhesive composition capable of showing an excellent anti-static performance, and solving a transferring problem of additives and a problem concerning a balance of low-rate and high-rate peel strength, by comprising a) an acrylic copolymer including a monomer having a functional group capable of chelating with a metal salt, and a hydrophobic monomer and b) a metal salt.

Abstract: The present invention relates to a transdermal patch comprising oxymorphone. The present invention also relates to processes for the preparation of the transdermal patches defined herein, as well as to the use of these patches for the treatment of pain.

Abstract: A vaginal preparation for the diagnosis of human female uterotubal patency and function, comprising particles having a nucleus absorbable by the tissues of the human body, and a coating for the nucleus which is dissolvable and non-absorbable by the tissues of the human body, inert and innocuous, the nucleus comprising at least one marker that can be released by the human body through an organic fluid, the coating being dissolvable and sensitive, for the purpose of the dissolution thereof, to time and/or changes in pH and/or temperature and/or another chemical/physical parameter along the route from the vaginal area to the tubal and pelvic area, the particles having a size, weight and ovoid shape corresponding approximately to those of spermatozoa.

Abstract: The present invention relates to compositions, devices and methods of delayed and sustained release of energy molecules for brain function to treat nocturnal hypoglycemia. The composition comprises an energy molecule required for human brain function; wherein the release of the energy molecule is delayed and then sustained over a period of time. The device is a transdermal delivery device comprising a reservoir layer containing the composition and a skin permeation enhancer formulation, an adhesive layer, a backing layer and a release liner. The method comprises administering the composition either orally or through the transdermal delivery device to a subject in need thereof immediately prior to going to sleep.

Abstract: A system and method are provided for the design and assembly of a device including a sensor capable and a compatible matrix material incorporated into a dressing. The sensor is capable of detecting analytes such as molecular oxygen, carbon dioxide, nitric oxides, dissolved analytes in plasma, and hydrogen ions, and the matrix is at least partially permeable to the analyte. The device emits a detectable signal when the sensor is excited in the presence of the analyte.

Abstract: A composite wound dressing and delivery apparatus includes a substantially transparent dressing layer having a lower surface that is coated with a pressure sensitive for applying the dressing layer over a wound to define a reservoir in which a negative pressure may be maintained. A substantially transparent backing layer adhered to the lower surface of the dressing layer in a releasable manner, and a vacuum port is centrally located on the dressing layer. The vacuum port is adapted to provide fluid communication between a vacuum source and the reservoir through the dressing layer. A targeting grid associated with either the dressing layer or the backing layer includes regularly spaced reference marks along at least two axes extending from the vacuum port.

Abstract: Provided is a patch providing sufficiently high absorbability of dexmedetomidine and less skin irritation. Hydrous adhesive patch comprising dexmedetomidine or a salt thereof and a water-soluble polymer.

Abstract: A super absorbent, honey-dosed foam/fiber composite, gap patterned wound dressing, comprising: a patterned foam/fiber composite structure having a gap patterned side and a non-gap patterned side, wherein the patterned side includes a pattern of foam/fiber gaps disposed between foam/fiber areas dosed with honey, where the pattern of foam/fiber gaps is formed by the honey-dosed areas, such that the patterned foam/fiber composite structure includes a layer of super absorbent material located substantially adjacent to the honey-dosed areas; and wherein a wound in contact with the gap patterned side discharges an exudate which substantially collects in the individual ones of the foam/fiber gaps causing honey in the individual ones of the honey-dosed areas to be substantially dispersed throughout a wound treatment zone and a portion of the exudate that is collected in the individual ones of the foam/fiber gaps is transferred to and collected in the super absorbent material.

Abstract: The present invention relates to a high adhesion dermal therapeutic system comprising an adhesive polymeric matrix with a salt of Diclofenac.

Abstract: Disclosed is a retention system for an electronic device including a base member for receiving the electronic device, a retention pad attached to the base member, a plurality of adhesive portions of the retention pad wherein the adhesive portions are dispersed, generally, in a gradient across the retention pad.

Abstract: Provided is a transdermal delivery system consisting of a backing layer, a drug-containing matrix layer, and a release layer, wherein the drug-containing matrix layer includes (a) donepezil or a pharmaceutically acceptable salt thereof as an active ingredient, (b) a mixture of high molecular weight polyisobutylene having a weight-average molecular weight ranging from 400,000 to 3,000,000 and low molecular weight polyisobutylene having a weight-average molecular weight ranging from 25,000 to 300,000 as an adhesive, and (c) a permeation enhancer in not more than 3% by weight based on the total weight of the drug-containing matrix layer.